- Home
- BKNG vs REGN Comparison
BKNG vs REGN Comparison
Compare BKNG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKNG
- REGN
- Stock Information
- Founded
- BKNG 1997
- REGN 1988
- Country
- BKNG United States
- REGN United States
- Employees
- BKNG N/A
- REGN N/A
- Industry
- BKNG Transportation Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- BKNG Consumer Discretionary
- REGN Health Care
- Exchange
- BKNG Nasdaq
- REGN Nasdaq
- Market Cap
- BKNG 119.8B
- REGN 116.3B
- IPO Year
- BKNG 1999
- REGN 1991
- Fundamental
- Price
- BKNG $3,731.35
- REGN $1,131.50
- Analyst Decision
- BKNG Buy
- REGN Buy
- Analyst Count
- BKNG 33
- REGN 24
- Target Price
- BKNG $4,059.59
- REGN $1,092.25
- AVG Volume (30 Days)
- BKNG 223.6K
- REGN 435.1K
- Earning Date
- BKNG 10-31-2024
- REGN 10-31-2024
- Dividend Yield
- BKNG 0.94%
- REGN N/A
- EPS Growth
- BKNG 23.46
- REGN N/A
- EPS
- BKNG 143.56
- REGN 37.77
- Revenue
- BKNG $22,399,000,000.00
- REGN $13,489,100,000.00
- Revenue This Year
- BKNG $9.72
- REGN $10.16
- Revenue Next Year
- BKNG $7.79
- REGN $8.60
- P/E Ratio
- BKNG $25.99
- REGN $29.96
- Revenue Growth
- BKNG 15.81
- REGN 6.46
- 52 Week Low
- BKNG $2,733.04
- REGN $769.19
- 52 Week High
- BKNG $4,144.32
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- BKNG 48.34
- REGN 43.98
- Support Level
- BKNG $3,592.28
- REGN $1,162.87
- Resistance Level
- BKNG $3,940.25
- REGN $1,192.54
- Average True Range (ATR)
- BKNG 69.36
- REGN 20.07
- MACD
- BKNG 6.39
- REGN -9.41
- Stochastic Oscillator
- BKNG 36.66
- REGN 3.08
About BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).